Cargando…

Extracellular vesicles mediate the communication between multiple myeloma and bone marrow microenvironment in a NOTCH dependent way

Multiple myeloma (MM) is an incurable hematologic neoplasm, whose poor prognosis is deeply affected by the propensity of tumor cells to localize in the bone marrow (BM) and induce the protumorigenic activity of normal BM cells, leading to events associated with tumor progression, including tumor ang...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giannandrea, Domenica, Platonova, Natalia, Colombo, Michela, Mazzola, Mara, Citro, Valentina, Adami, Raffaella, Maltoni, Filippo, Ancona, Silvia, Dolo, Vincenza, Giusti, Ilaria, Basile, Andrea, Pistocchi, Anna, Cantone, Laura, Bollati, Valentina, Casati, Lavinia, Calzavara, Elisabetta, Turrini, Mauro, Lesma, Elena, Chiaramonte, Raffaella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Article - Plasma Cell Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425323/ https://www.ncbi.nlm.nih.gov/pubmed/35263984 http://dx.doi.org/10.3324/haematol.2021.279716

Ejemplares similares

Restoring Tissue Homeostasis at Metastatic Sites: A Focus on Extracellular Vesicles in Bone Metastasis
por: Giannandrea, Domenica, et al.
Publicado: (2021)

Sex Steroid Regulation of Oxidative Stress in Bone Cells: An In Vitro Study
por: Sibilia, Valeria, et al.
Publicado: (2021)

Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins
por: Taiana, Elisa, et al.
Publicado: (2022)

Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance
por: Colombo, Michela, et al.
Publicado: (2020)

Extracellular Vesicles Enhance Multiple Myeloma Metastatic Dissemination
por: Colombo, Michela, et al.
Publicado: (2019)

Re-establishing Apoptosis Competence in Bone Associated Cancers via Communicative Reprogramming Induced Through Notch Signaling Inhibition
por: Colombo, Michela, et al.
Publicado: (2019)

The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma
por: Platonova, Natalia, et al.
Publicado: (2023)

Jagged Ligands Enhance the Pro-Angiogenic Activity of Multiple Myeloma Cells
por: Palano, Maria Teresa, et al.
Publicado: (2020)

Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu
por: Colombo, Michela, et al.
Publicado: (2018)

Differential Modulation of Matrix Metalloproteinases-2 and -7 in LAM/TSC Cells
por: Ancona, Silvia, et al.
Publicado: (2021)

Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment
por: Soncini, Debora, et al.
Publicado: (2021)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
por: Capra, Marcelo, et al.
Publicado: (2021)

Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities
por: Giesen, Nicola, et al.
Publicado: (2022)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
por: García-Guerrero, Estefanía, et al.
Publicado: (2022)

Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis
por: Mangiacavalli, Silvia, et al.
Publicado: (2022)

An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence
por: Holler, Maximilian, et al.
Publicado: (2022)

Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling
por: Lawless, Sarah, et al.
Publicado: (2022)

High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex
por: Zhou, Xiang, et al.
Publicado: (2023)

Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden
por: Moore, Kari Lenita Falck, et al.
Publicado: (2022)

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
por: Schavgoulidze, Anaïs, et al.
Publicado: (2022)

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
por: Talbot, Alexis, et al.
Publicado: (2023)

IgM monoclonal gammopathy of undetermined significance: clinicopathologic features with and without IgM-related disorders
por: Bruehl, Frido K., et al.
Publicado: (2023)

Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
por: Puertas, Borja, et al.
Publicado: (2023)

Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs
por: Takamatsu, Hiroyuki, et al.
Publicado: (2023)

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
por: McCurdy, Arleigh, et al.
Publicado: (2023)

IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma
por: Pisano, Michael D., et al.
Publicado: (2023)

Amyloidogenic light chains impair plasma cell survival
por: Pick, Marjorie, et al.
Publicado: (2023)

Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study
por: Sigurbergsdóttir, Aðalbjörg Ýr, et al.
Publicado: (2023)

LAM Cells as Potential Drivers of Senescence in Lymphangioleiomyomatosis Microenvironment
por: Bernardelli, Clara, et al.
Publicado: (2022)

Reduction of Movement in Neurological Diseases: Effects on Neural Stem Cells Characteristics
por: Adami, Raffaella, et al.
Publicado: (2018)

P847: BIOLOGICAL AND MOLECULAR CHARACTERIZATION OF IN SILICO IDENTIFIED PUTATIVE INHIBITORS OF PARASPECKLE ASSEMBLY WITH POTENTIAL ANTI-MULTIPLE MYELOMA ACTIVITY.
por: Traini, Valentina, et al.
Publicado: (2023)

Notch signaling deregulation in multiple myeloma: A rational molecular target
por: Colombo, Michela, et al.
Publicado: (2015)

Plasmas en todas partes /
por: Bravo, Silvia
Publicado: (1991)

Plasmas en todas partes /
por: Bravo, Silvia
Publicado: (2001)

Primary TSC2(-/meth) Cells Induce Follicular Neogenesis in an Innovative TSC Mouse Model
por: Bernardelli, Clara, et al.
Publicado: (2022)

Role of Prolactin Receptors in Lymphangioleiomyomatosis
por: Alkharusi, Amira, et al.
Publicado: (2016)

Anti-EGFR Antibody Reduces Lung Nodules by Inhibition of EGFR-Pathway in a Model of Lymphangioleiomyomatosis
por: Lesma, Elena, et al.
Publicado: (2015)

Isolation and Characterization of Cetacean Cell-Derived Extracellular Vesicles
por: Moccia, Valentina, et al.
Publicado: (2023)

Extracellular Vesicles in Prostate Cancer: New Future Clinical Strategies?
por: Giusti, Ilaria, et al.
Publicado: (2014)

Identification of small molecules uncoupling the Notch::Jagged interaction through an integrated high-throughput screening
por: Platonova, Natalia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lvoe7rp4dhikmln92dm1anpnrt